The PI-3-Kinase P110α Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis

Area of Science:

• Immunology
• Molecular Biology
• Rheumatology

Background:

• Phosphatidylinositol 3-kinase (PI3K) enzymes are crucial in inflammation and autoimmune responses.
• The specific roles of PI3K catalytic subunit isoforms in autoimmune diseases like rheumatoid arthritis (RA) remain unclear.
• PI3K is a potential immune modulation hub in RA, involving innate and adaptive immunity.

Purpose of the Study:

• To investigate the role of the p110α catalytic subunit of PI3K in T cells during collagen-induced arthritis (CIA).
• To explore the therapeutic potential of targeting p110α in T-cell-directed therapies for autoimmune diseases.

Main Methods:

• Utilized a mouse transgenic model with T-cell-specific deletion of the p110α catalytic chain (p110α^-/-ΔT).
• Assessed disease modulation in collagen-induced arthritis (CIA) models, including established and pre-arthritis phases.
• Analyzed immune cell populations, antibody titers (IgG1, IgG2a), cytokine levels (IL-6, IL-17A), and T-cell signaling pathways (ICOS, Akt phosphorylation) in vitro and in vivo.

Main Results:

• T-cell-specific deletion of p110α (p110α^-/-ΔT) decreased disease prevalence and severity in CIA models.
• p110α^-/-ΔT mice exhibited altered antibody responses (higher IgG1/IgG2a ratio), reduced T-cell proliferation and IL-17A secretion, and changes in naive/effector CD4+ T cell subpopulations.
• In vitro studies showed increased CXCR5, CD44, and ICOS expression on p110α-deficient T cells, with defective ICOS-induced Akt signaling.

Conclusions:

• The p110α catalytic chain of PI3K plays a significant role in modulating collagen-induced arthritis.
• Targeting p110α in T cells can diminish disease incidence and prevalence, suggesting a novel therapeutic strategy for autoimmune diseases.
• The findings open new avenues for developing T-cell-directed therapies for autoimmune conditions by modulating PI3K signaling.